Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients

A 5-Year Follow-up Study

H. T. Khosroshahi, Mohammadali Mohajel Shoja, A. Peyrovifar, S. R. Hashemi, M. Amjadi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplantation, is associated with several dose-dependent hematologic and gastrointestinal side effects that may require dose reduction or even discontinuation. The aim of this study was to compare renal allograft function and acute rejection episodes among kidney allograft recipients who were on 2 regimens of MMF for at least 5 years. Materials and Methods: This prospective cohort of 55 kidney allograft recipients was followed for deterioration of allograft function, evidence of acute rejection, and allograft survival. Twenty-two patients (40%) underwent MMF dose reduction to 1.35 to 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after kidney transplantation. The remaining patients (group 2, n = 33) were continued on MMF (2 g/d). All patients were followed for at least 5 years after transplantation. Renal function tests (blood urea and serum creatinine) were measured monthly for 2 years and then every 2 months. Statistical analysis was performed using SPSS 11.0 (Student t test). P ≤ .05 was considered significant. Results: The 2 groups were comparable regarding age, gender, and immunosuppressive medications. The renal function tests were comparable at the end of the study. Mean blood urea values were 44.8 ± 5.8 and 46.8 ± 6.8 mg/dL in groups 1 and 2 (P > .05); mean serum creatinine values were 1.32 ± 0.14 and 1.38 ± 0.21 mg/dL, respectively (P > .05). There were 2 graft losses and 1 patient loss in group 2. There were also 2 graft losses among group 1 patients. Conclusion: Our study showed that MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired allograft function at 5 years.

Original languageEnglish (US)
Pages (from-to)2797-2799
Number of pages3
JournalTransplantation Proceedings
Volume41
Issue number7
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Mycophenolic Acid
Allografts
Kidney
Immunosuppressive Agents
Kidney Transplantation
Urea
Creatinine
Transplants
Transplant Recipients
Serum
Transplantation
Economics
Students

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Khosroshahi, H. T., Mohajel Shoja, M., Peyrovifar, A., Hashemi, S. R., & Amjadi, M. (2009). Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients: A 5-Year Follow-up Study. Transplantation Proceedings, 41(7), 2797-2799. https://doi.org/10.1016/j.transproceed.2009.07.036

Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients : A 5-Year Follow-up Study. / Khosroshahi, H. T.; Mohajel Shoja, Mohammadali; Peyrovifar, A.; Hashemi, S. R.; Amjadi, M.

In: Transplantation Proceedings, Vol. 41, No. 7, 01.09.2009, p. 2797-2799.

Research output: Contribution to journalArticle

Khosroshahi, HT, Mohajel Shoja, M, Peyrovifar, A, Hashemi, SR & Amjadi, M 2009, 'Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients: A 5-Year Follow-up Study', Transplantation Proceedings, vol. 41, no. 7, pp. 2797-2799. https://doi.org/10.1016/j.transproceed.2009.07.036
Khosroshahi, H. T. ; Mohajel Shoja, Mohammadali ; Peyrovifar, A. ; Hashemi, S. R. ; Amjadi, M. / Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients : A 5-Year Follow-up Study. In: Transplantation Proceedings. 2009 ; Vol. 41, No. 7. pp. 2797-2799.
@article{a804382b578a4401a1015130441f600f,
title = "Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients: A 5-Year Follow-up Study",
abstract = "Objective: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplantation, is associated with several dose-dependent hematologic and gastrointestinal side effects that may require dose reduction or even discontinuation. The aim of this study was to compare renal allograft function and acute rejection episodes among kidney allograft recipients who were on 2 regimens of MMF for at least 5 years. Materials and Methods: This prospective cohort of 55 kidney allograft recipients was followed for deterioration of allograft function, evidence of acute rejection, and allograft survival. Twenty-two patients (40{\%}) underwent MMF dose reduction to 1.35 to 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after kidney transplantation. The remaining patients (group 2, n = 33) were continued on MMF (2 g/d). All patients were followed for at least 5 years after transplantation. Renal function tests (blood urea and serum creatinine) were measured monthly for 2 years and then every 2 months. Statistical analysis was performed using SPSS 11.0 (Student t test). P ≤ .05 was considered significant. Results: The 2 groups were comparable regarding age, gender, and immunosuppressive medications. The renal function tests were comparable at the end of the study. Mean blood urea values were 44.8 ± 5.8 and 46.8 ± 6.8 mg/dL in groups 1 and 2 (P > .05); mean serum creatinine values were 1.32 ± 0.14 and 1.38 ± 0.21 mg/dL, respectively (P > .05). There were 2 graft losses and 1 patient loss in group 2. There were also 2 graft losses among group 1 patients. Conclusion: Our study showed that MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired allograft function at 5 years.",
author = "Khosroshahi, {H. T.} and {Mohajel Shoja}, Mohammadali and A. Peyrovifar and Hashemi, {S. R.} and M. Amjadi",
year = "2009",
month = "9",
day = "1",
doi = "10.1016/j.transproceed.2009.07.036",
language = "English (US)",
volume = "41",
pages = "2797--2799",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Mycophenolate Mofetil Dose Reduction in Renal Transplant Recipients

T2 - A 5-Year Follow-up Study

AU - Khosroshahi, H. T.

AU - Mohajel Shoja, Mohammadali

AU - Peyrovifar, A.

AU - Hashemi, S. R.

AU - Amjadi, M.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Objective: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplantation, is associated with several dose-dependent hematologic and gastrointestinal side effects that may require dose reduction or even discontinuation. The aim of this study was to compare renal allograft function and acute rejection episodes among kidney allograft recipients who were on 2 regimens of MMF for at least 5 years. Materials and Methods: This prospective cohort of 55 kidney allograft recipients was followed for deterioration of allograft function, evidence of acute rejection, and allograft survival. Twenty-two patients (40%) underwent MMF dose reduction to 1.35 to 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after kidney transplantation. The remaining patients (group 2, n = 33) were continued on MMF (2 g/d). All patients were followed for at least 5 years after transplantation. Renal function tests (blood urea and serum creatinine) were measured monthly for 2 years and then every 2 months. Statistical analysis was performed using SPSS 11.0 (Student t test). P ≤ .05 was considered significant. Results: The 2 groups were comparable regarding age, gender, and immunosuppressive medications. The renal function tests were comparable at the end of the study. Mean blood urea values were 44.8 ± 5.8 and 46.8 ± 6.8 mg/dL in groups 1 and 2 (P > .05); mean serum creatinine values were 1.32 ± 0.14 and 1.38 ± 0.21 mg/dL, respectively (P > .05). There were 2 graft losses and 1 patient loss in group 2. There were also 2 graft losses among group 1 patients. Conclusion: Our study showed that MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired allograft function at 5 years.

AB - Objective: Mycophenolate mofetil (MMF), an immunosuppressant that is widely used in renal transplantation, is associated with several dose-dependent hematologic and gastrointestinal side effects that may require dose reduction or even discontinuation. The aim of this study was to compare renal allograft function and acute rejection episodes among kidney allograft recipients who were on 2 regimens of MMF for at least 5 years. Materials and Methods: This prospective cohort of 55 kidney allograft recipients was followed for deterioration of allograft function, evidence of acute rejection, and allograft survival. Twenty-two patients (40%) underwent MMF dose reduction to 1.35 to 0.23 g/d due to perceived side effects or economic reasons (group 1). The mean time for this change was 4.2 ± 2.1 months after kidney transplantation. The remaining patients (group 2, n = 33) were continued on MMF (2 g/d). All patients were followed for at least 5 years after transplantation. Renal function tests (blood urea and serum creatinine) were measured monthly for 2 years and then every 2 months. Statistical analysis was performed using SPSS 11.0 (Student t test). P ≤ .05 was considered significant. Results: The 2 groups were comparable regarding age, gender, and immunosuppressive medications. The renal function tests were comparable at the end of the study. Mean blood urea values were 44.8 ± 5.8 and 46.8 ± 6.8 mg/dL in groups 1 and 2 (P > .05); mean serum creatinine values were 1.32 ± 0.14 and 1.38 ± 0.21 mg/dL, respectively (P > .05). There were 2 graft losses and 1 patient loss in group 2. There were also 2 graft losses among group 1 patients. Conclusion: Our study showed that MMF dose reduction was not associated with an increased risk of acute renal allograft rejection or impaired allograft function at 5 years.

UR - http://www.scopus.com/inward/record.url?scp=70149109806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149109806&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2009.07.036

DO - 10.1016/j.transproceed.2009.07.036

M3 - Article

VL - 41

SP - 2797

EP - 2799

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 7

ER -